# A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

> **NCT04904913** · PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 328 (actual)

## Conditions studied

- Overweight/ Obesity

## Interventions

- **DRUG:** IBI362
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04904913
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-08
- **Primary completion:** 2023-03-29
- **Final completion:** 2023-12-06
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04904913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04904913, "A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04904913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*